Impact of exogenous glucocorticoid use on salivary cortisol measurements among adults with asthma and rhinitis.
The diurnal rhythm of cortisol secretion in chronic disease can reflect the interactions between exogenous and endogenous factors. Exogenous glucocorticoid use may impact salivary cortisol measurements, but this has not been well-studied in ambulatory settings. In this report salivary cortisol levels were used to evaluate aspects of the diurnal rhythm of cortisol secretion within an ambulatory population of patients with asthma and allergic rhinitis. 183 persons with asthma with or without concomitant rhinitis and 34 persons with rhinitis alone were asked to collect at home, two saliva samples, 30 min after awakening and 12h later. The salivary cortisol levels were quantified by enzyme immunoassay. The recent use of glucocorticoids in the study group was determined by interview and direct examination of medications. We report that the median salivary cortisol levels 30 min post-awakening significantly differed by exogenous steroid status: no glucocorticoid use (n = 91), 10.1 nmol/l; nasal gluco-corticoid use alone (n = 25), 11.4 nmol/l; inhaled glucocorticoids (with or without concomitant nasal glucocorticoids; n = 76), 9.0 nmol/l; systemic glucocorticoids (n = 17), 4.0 nmol/l; (P = 0.02). 12-h post-awakening salivary cortisol values among the groups were similar (P = 0.85). The median 30-min post-awakening cortisol differed significantly by type and amount of inhaled steroid used: non-fluticasone users (n = 21), 11.5 nmol/l; lower dose fluticasone (<800 microg per day, n = 35); 9.2 nmol/l; and higher dose fluticasone (> or =800 microg, n=20), 5 nmol/l; (P=0.01). We conclude that in an ambulatory setting, exogenous glucocorticoid use can decrease the 30 min post-awakening but not the 12-h post-awakening salivary cortisol levels, an effect that should be taken into account in assessing the effects of other potential determinants on cortisol secretion.
Masharani
Umesh
U
Department of Medicine, University of California San Francisco, 94143-1222, USA. ubm@itsa.ucsf.edu
Shiboski
Stephen
S
Eisner
Mark D
MD
Katz
Patricia P
PP
Janson
Susan L
SL
Granger
Douglas A
DA
Blanc
Paul D
PD
D000280:Administration, Inhalation; D000281:Administration, Intranasal; D000284:Administration, Oral; D000328:Adult; D001249:Asthma / Q000188:drug therapy / Q000378:metabolism*; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000378:metabolism; D006801:Humans; D006854:Hydrocortisone / Q000032:analysis / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D012220:Rhinitis / Q000188:drug therapy / Q000378:metabolism*; D012463:Saliva / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D012469:Salivary Glands / Q000378:metabolism*; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric
D005938:Glucocorticoids; D006854:Hydrocortisone